选择性5-羟色胺再摄取抑制剂与脑出血风险及预后
该研究基于ERICH研究的事后分析,纳入2287例脑出血病例和2895例对照,评估脑出血前SSRI使用是否增加脑出血风险及脑出血后SSRI使用是否改善预后。结果显示脑出血前SSRI使用与脑出血风险无关,但脑出血后新使用SSRI与3个月不良神经功能结局相关。
要点
- 脑出血前使用SSRI未增加脑出血风险(OR 0.824,95%CI 0.632-1.074)。
- 脑出血后新使用SSRI与3个月不良改良Rankin量表评分相关(OR 1.673,95%CI 1.162-2.408;P=0.006)。
- 倾向性评分分析显示类似趋势但未达统计学显著性(P=0.107)。
核心结论
- 在大规模多种族队列中,脑出血前SSRI使用与脑出血风险增加无关。
- 脑出血后SSRI使用与3个月不良神经功能结局相关。
研究设计与样本
- ERICH研究(脑出血的种族/民族差异研究)的事后分析,最终队列包含2287例脑出血病例和2895例对照。
- SSRI使用分为未使用、仅脑出血前使用、脑出血前后连续使用和仅脑出血后新使用四类。
- 采用多变量模型分析脑出血前SSRI使用与脑出血风险的关联(病例对照集)以及脑出血后SSRI使用与3个月结局的关联(病例集)。
- 探索性分析评估种族/民族的影响。
主要发现
- 脑出血前SSRI使用与脑出血风险无关(OR 0.824,95%CI 0.632-1.074),也未增强抗凝或抗血小板药物的脑出血风险。
- 脑出血后新使用SSRI与3个月不良改良Rankin量表评分相关(OR 1.673,95%CI 1.162-2.408;P=0.006)。
- 倾向性评分分析显示类似趋势但未达统计学显著性(P=0.107)。
- 按种族/民族分层,西班牙裔中脑出血前SSRI使用与脑出血风险降低相关(OR 0.513,95%CI 0.301-0.875;P=0.014),非西班牙裔白人和黑人中无此关联。
- 任何种族/民族组中脑出血后SSRI使用与3个月结局均无关联。
临床怎么用
- 脑出血前使用SSRI不应被视为脑出血的风险因素。
- 脑出血后新启用SSRI需谨慎评估,可能与3个月不良神经功能结局相关。
局限性
- 为事后分析,可能存在残余混杂。
- 倾向性评分分析未达统计学显著性,需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- Selective serotonin reuptake inhibitors (SSRIs) have a well-established association with bleeding complications and conflicting reports on outcome after stroke. We sought to evaluate whether pre-intracerebral hemorrhage (ICH) SSRI use increased ICH risk and post-ICH SSRI use improved ICH outcome. Methods- Through post hoc analysis of the ERICH study (Ethnic/Racial Variations of Intracerebral Hemorrhage), SSRI use was categorized into no use, pre-ICH only, pre- and post-ICH use (termed "continuous"), and post-ICH only (termed "new"). Using multivariable modeling, associations were sought between pre-ICH SSRI use and ICH risk in the case-control set, and associations between post-ICH SSRI use and 3-month outcome were analyzed in the ICH case set. Exploratory analyses sought to assess influence of race/ethnicity in models. Results- The final study cohort consisted of 2287 ICH cases and 2895 controls. Pre-ICH SSRI use was not associated with ICH risk (odds ratio, 0.824 [95% CI, 0.632-1.074]) nor potentiation of ICH risk with anticoagulant or antiplatelet use. New post-ICH SSRI use was associated with unfavorable modified Rankin Scale score at 3 months after ICH (odds ratio, 1.673 [95% CI, 1.162-2.408]; P=0.006) in multivariable analyses. Additional propensity score analysis indicated a similar trend but did not reach statistical significance (P=0.107). When stratified by race/ethnicity, multivariable modeling demonstrated reduced ICH risk with pre-ICH SSRI use in Hispanics (odds ratio, 0.513 [95% CI, 0.301-0.875]; P=0.014), but not non-Hispanic whites or blacks, and no associations between post-ICH SSRI use and 3-month outcome in any racial/ethnic group. Conclusions- In a large multiethnic cohort, pre-ICH SSRI use was not associated with increased ICH risk, but post-ICH SSRI use was associated with unfavorable 3-month neurological outcome after ICH. Registration- URL: https://www.clinicaltrials.gov; Unique identifier: NCT01202864.
引用
- Liu L, Fuller M, Behymer TP, et al. Selective Serotonin Reuptake Inhibitors and Intracerebral Hemorrhage Risk and Outcome. Stroke. 2020. PMID: 32126942. doi:10.1161/STROKEAHA.119.028406
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。